Reed Catherine, Hong Jihyung, Novick Diego, Lenox-Smith Alan, Happich Michael
Global Health Outcomes, Eli Lilly and Company, Windlesham, Surrey, UK.
Personal Social Services Research Unit, London School of Economics and Political Science, London, UK.
Pragmat Obs Res. 2013 Sep 27;4:27-37. doi: 10.2147/POR.S49746. eCollection 2013.
To determine the incidence of diabetic peripheral neuropathic pain (DPNP) in the United Kingdom (UK) primary care population using the General Practice Research Database (GPRD).
This retrospective cohort study identified incident cases of DPNP in the UK GPRD between July 1, 2002 and June 30, 2011, using diagnostic codes. Trends in the incidence rate were examined by dividing the study period into 3-year periods: (1) July 1, 2002-June 30, 2005; (2) July 1, 2005-June 30, 2008; and (3) July 1, 2008-June 30, 2011. Patient characteristics (age, sex, comorbidities) and initial pharmacological treatment were described; the proportion of patients with incident DPNP, who had previously been screened for neuropathic symptoms, was determined.
Among almost 7.5 million persons contributing 38,118,838 person-years of observations in the GPRD, 6,779 new cases of DPNP were identified (45.5%, women), giving an incidence rate of 17.8 per 100,000 person-years (95% confidence interval [CI] 17.4-18.2). The incidence of DPNP increased with age, but it was stable over the three consecutive 3-year periods: 17.9, 17.2, and 18.4 cases per 100,000 person-years. Of the 6,779 patients with incident DPNP, 15.5% had prior neuropathic screening during the study period. The majority of patients with incident DPNP (84.5%) had a treatment for pain initiated within 28 days of first diagnosis. The most common first-line treatments prescribed were tricyclic antidepressants (27.2%), anticonvulsants (17.0%), and nonsteroidal anti-inflammatory drugs (14.9%), with 26.6% of patients receiving combination therapy as their initial treatment.
The incidence of DPNP in UK primary care has remained steady over the past 10 years. Our results suggest that DPNP is underdiagnosed, and initial treatment prescribed does not follow clinical guidelines.
利用全科医疗研究数据库(GPRD)确定英国初级保健人群中糖尿病性周围神经病理性疼痛(DPNP)的发病率。
这项回顾性队列研究通过诊断编码确定了2002年7月1日至2011年6月30日期间英国GPRD中DPNP的新发病例。通过将研究期分为3年时间段来检查发病率趋势:(1)2002年7月1日至2005年6月30日;(2)2005年7月1日至2008年6月30日;以及(3)2008年7月1日至2011年6月30日。描述了患者特征(年龄、性别、合并症)和初始药物治疗情况;确定了之前接受过神经病理性症状筛查的新发DPNP患者的比例。
在GPRD中近750万人贡献了38118838人年的观察数据,共识别出6779例DPNP新病例(45.5%为女性),发病率为每10万人年17.8例(95%置信区间[CI] 17.4 - 18.2)。DPNP的发病率随年龄增加,但在连续三个3年时间段内保持稳定:每10万人年分别为17.9例、17.2例和18.4例。在6779例新发DPNP患者中,15.5%在研究期间曾接受过神经病理性筛查。大多数新发DPNP患者(84.5%)在首次诊断后28天内开始接受疼痛治疗。最常用的一线治疗药物为三环类抗抑郁药(27.2%)、抗惊厥药(17.0%)和非甾体抗炎药(14.9%),26.6%的患者初始治疗接受联合治疗。
过去10年中,英国初级保健中DPNP的发病率保持稳定。我们的结果表明DPNP诊断不足,且初始治疗未遵循临床指南。